66th ASH Annual Meeting & Exposition congress coverage

Stay up to date with the latest developments in GvHD from the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US. Catch up with our live social media here.  

CONGRESS #ASH24 | PRESENTATION@yanminzhao_zju, Zhejiang University School of Medicine presented results from a study of Rovadicitinib in SR-refractory or -dependant cGvHD. BOR was 96.6% in 10mg BID and 80.0% in 15mg BID groups. Organ-specific BOR was highest in the liver (100%)… pic.twitter.com/8B3qUgIcyP

— GvHD Hub (@gvhd_hub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Hannah Choe, @OSUCCC_James discussed an analysis from the Agave-201 Study. Organ-specific response with axatilimab was most rapid for esophagus, and lower and upper GI tract, and slowest for eyes and skin. Safety profile in responders was dose… pic.twitter.com/MTgrZPU15P

— GvHD Hub (@gvhd_hub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Xiaodong Mo, Peking University Peoples’ Hospital, presented results from a phase II study of Pimicotinib (ABSK021) in cGvHD. ORR was 64% in the 20mg group within 24 weeks. Median time to response 4 weeks. Most common TEAE was AST increased (28%) in… pic.twitter.com/6bFUox01ao

— GvHD Hub (@gvhd_hub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Robert Zeiser, German Cancer Consortium discusses results from STARGAZE, a phase 2 trial of apraglutide in SR-GI aGvHD. The majority of patients had Grade 3 or 4 disease. Lower-GI ORR was 54.8% at Day 28, and 48.4% at Day 91. All patients… pic.twitter.com/IAxkvqudkz

— GvHD Hub (@gvhd_hub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Jenny Paredes, @cityofhope discussed the role of dietary fiber in allo-HCT. A high fiber diet was positively correlated with OS, and negatively associated with aGvHD risk. In mice models, 12% cellulose was associated with increased GvHD survival and… pic.twitter.com/FzEuBrD2Cn

— GvHD Hub (@gvhd_hub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Yu Akahoshi, @IcahnMountSinai discussed refinement of Day 28 Treatment Response Criteria for aGvHD. Day 28 refined response is more accurate at precicting 6 month NRM compared to Day 28 OS. Refined responders are more likley to have better long-term… pic.twitter.com/uBurT4grm9

— GvHD Hub (@gvhd_hub) December 8, 2024

CONGRESS #ASH24 | PRESENTATION@sameem_abedin, @MedicalCollege presented results from a phase II trial of de-esclated PTCy and rux for GvHD prophylaxsis. There was no excess NRM in the first 100 days on study. Of 18 evaluable pts, 22% experienced relapse. Estimated 1-yr OS was… pic.twitter.com/tFASJLTV76

— GvHD Hub (@gvhd_hub) December 10, 2024

CONGRESS #ASH24 | PRESENTATION@sameem_abedin, @MedicalCollege discussed results from the BMT CTN 1703 study of PTCy for GvhD prophylaxis in older pts. Estimated TRM was 4.6% in the PTCy arm vs 20% in the Tac/MTX arm. There were similar rates of toxicities in the arms. Estimated… pic.twitter.com/nF1o54Mvw7

— GvHD Hub (@gvhd_hub) December 10, 2024

CONGRESS #ASH24 | PRESENTATION
Ryotaro Nakamura, @cityofhope presented data from a phase IIa final analysis, of addition of itacitinib to tacrolimus/sirolimus GvHD prophylaxis. All pts has neutrophil engraftment, with estimated 1-yr GRFS of 54%. Improved IST tapering could reduce… pic.twitter.com/pHNqCx6lYD

— GvHD Hub (@gvhd_hub) December 10, 2024

CONGRESS #ASH24 | PRESENTATION
Yanmin Zhao, Zhejiang University School of Medicine discussed a trial of low dose ruxolitinib for GvHD prophylaxis after HSCT. Incidence of Grade II-IV aGvHD at Day 100 was 7.8% for rux vs 36.9% for control. Neurophil and platelet engraftment was… pic.twitter.com/AKxbDITVVE

— GvHD Hub (@gvhd_hub) December 10, 2024

CONGRESS #ASH24 | POSTER @Florent_Malard, @Sorbonne_Univ_ presented a poster on the early access program for MaaT013. Responders had increased OS vs non-responders, MaaT013 was safe in pts with GI-aGvHD. Results from the phase III trial expected soon. Follow our live feed for… pic.twitter.com/NXB5pHFFo8

— GvHD Hub (@gvhd_hub) December 10, 2024

CONGRESS #ASH24 | POSTER
Melhem M. Solh, Northside Hospital Cancer Institute presented a poster on ECP for GvHD. OS at 6 mo was 76% for the ECP group vs 68% for the non-ECP group. NIH score reduction was greater in the ECP group. There was no difference in 3-yr OS (81.5% vs… pic.twitter.com/vAiLkrlMNh

— GvHD Hub (@gvhd_hub) December 10, 2024

CONGRESS #ASH24 | POSTER @Jkuball, @UMCUtrecht, presented a poster on MSCs in SR-aGvHD. ORR at day 7 was 26.5% and 44.5% at day 28. At 12 mo, NRM was 58.8%. 84.8% of day 7 responders maintained response to day 28. Follow our live feed for more updates: https://t.co/u90LXlAb8E… pic.twitter.com/7AjpOO6fYE

— GvHD Hub (@gvhd_hub) December 10, 2024